| |
EBMT
|
MEA
|
|---|
|
Variable category
|
Total (59, 100%)
|
Reinfected group (7, 11.9%)
|
Continuously eradicated group (52, 88.1%)
|
p-value*
|
Total (116, 100%)
|
Reinfected group (19, 16.4%)
|
Continuously eradicated group (97, 83.6%)
|
p-value*
|
|---|
|
Gender
|
(N = 59)
|
(n = 7)
|
(n = 52)
| |
(N = 116)
|
(n = 19)
|
(n = 97)
| |
|
Male
|
(35, 59.3%)
|
(4, 57.1%)
|
(31, 59.6%)
|
0.816
|
(69, 59.5%)
|
(12, 63.2%)
|
(57, 58.8%)
|
0.353
|
|
Female
|
(24, 40.7%)
|
(3, 42.9%)
|
(21, 40.4%)
| |
(47, 40.5%)
|
(7, 36.8%)
|
(40, 41.2%)
| |
|
Age (mean ± SD)
|
(N = 59)
|
(n = 7)
|
(n = 52)
| |
(N = 116)
|
(n = 19)
|
(n = 97)
| |
|
(56.1 ± 9.3)
|
(59.9 ± 9.8)
|
(55.6 ± 9.2)
|
(56.8 ± 9.5)
|
(56.7 ± 9.4)
|
(56.8 ± 9.6)
|
|
20-29
|
(1, 1.7%)
|
(0, 0.0%)
|
(1, 1.9%)
|
0.306
|
(1, 0.9%)
|
(0, 0.0%)
|
(1, 1.0%)
|
0.479
|
|
30-39
|
(1, 1.7%)
|
(0, 0.0%)
|
(1, 1.9%)
| |
(3, 2.6%)
|
(0, 0.0%)
|
(3, 3.1%)
| |
|
40-49
|
(13, 22.0%)
|
(2, 22.2%)
|
(11, 21.2%)
| |
(21, 18.1%)
|
(6, 31.6%)
|
(15, 15.5%)
| |
|
50-59
|
(21, 35.6%)
|
(1, 14.3%)
|
(20, 38.5%)
| |
(40, 34.5%)
|
(5, 26.3%)
|
(35, 36.1%)
| |
|
60-69
|
(20, 33.9%)
|
(3, 42.9%)
|
(17, 32.7%)
| |
(42, 36.2%)
|
(6, 31.6%)
|
(36, 37.1%)
| |
|
70-79
|
(3, 5.1%)
|
(1, 14.3%)
|
(2, 3.8%)
| |
(8, 10.5%)
|
(2, 10.5%)
|
(6, 6.2%)
| |
|
80-89
|
(0, 0.0%)
|
(0, 0.0%)
|
(0, 0.0%)
| |
(1, 0.6%)
|
(0, 0.0%)
|
(1, 1.0%)
| |
|
Clinical diagnosis
|
(N = 59)
|
(n = 7)
|
(n = 52)
| |
(N = 116)
|
(n = 19)
|
(n = 97)
| |
|
Early gastric cancer
|
(11, 18.6%)
|
(0, 0.0%)
|
(11, 21.2%)
|
0.198
|
(29, 25.0%)
|
(7, 36.8%)
|
(22, 22.7%)
|
0.77
|
|
Dysplasia
|
(3, 5.1%)
|
(1, 14.3%)
|
(2, 3.8%)
| |
(16, 13.8%)
|
(3, 15.8%)
|
(13, 13.4%)
| |
|
Peptic ulcer disease
|
(17, 28.8%)
|
(4, 57.1%)
|
(13, 25.0%)
| |
(17, 14.7%)
|
(3, 15.8%)
|
(14, 14.4%)
| |
|
Chronic gastritis
|
(28, 47.5%)
|
(2, 28.6%)
|
(26, 50.0%)
| |
(54, 46.6%)
|
(6, 31.6%)
|
(48, 49.5%)
| |
|
Histological AG in either antrum or body
|
(N = 37)
|
(n =6)
|
(n = 31)
| |
(N = 79)
|
(n = 14)
|
(n = 65)
| |
|
Yes
|
(21, 56.8%)
|
(5, 83.3%)
|
(16, 51.6%)
|
0.113
|
(46, 58.2%)
|
(9, 64.3%)
|
(37, 56.9%)
|
0.575
|
|
No
|
(16, 43.2%)
|
(1, 16.7%)
|
(15, 48.4%)
| |
(33, 41.8%)
|
(5, 35.7%)
|
(28, 43.1%)
| |
|
Histological IM in either antrum or body
|
(N = 47)
|
(n = 6)
|
(n = 41)
| |
(N = 97)
|
(n = 15)
|
(n = 82)
| |
|
Yes
|
(23, 48.9%)
|
(4, 66.7%)
|
(21, 51.2%)
|
0.193
|
(61, 62.9%)
|
(8, 53.3%)
|
(53, 64.6%)
|
0.52
|
|
No
|
(24, 51.1%)
|
(2, 33.3%)
|
(20, 48.8%)
| |
(36, 37.1%)
|
(7, 46.7%)
|
(29, 35.4%)
| |
-
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atrophic gastritis; IM, intestinal metaplasia.
- All of early gastric cancer patients were cured by endoscopic submucosal dissection.
-
* P-value for Log-rank test.
